FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:409-411 January 25, 2007 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Ullmann, A. J. Related Article by Cornely, O. A. PubMed Citation

Invasive fungal diseases contribute substantially to death and illness associated with the prolonged, profound neutropenia resulting from intensive chemotherapy for hematologic cancers and from myeloablation for allogeneic hematopoietic stem-cell transplantation. In addition, the development of graft-versus-host disease (GVHD) puts transplant recipients at risk for infection for several weeks or months after engraftment.¹ Given the high mortality associated with invasive fungal diseases and our inability to recognize active cases reliably, it is not surprising that prophylaxis is perceived as a sensible therapeutic approach.

More than a decade ago, fluconazole was shown to be effective for preventing candida infection.² However, aspergillus species . . . [Full Text of this Article]

Source Information

From the Department of Blood Transfusion and Transplant Immunology and the Department of Hematology, University Medical Center St. Radboud, Nijmegen, the Netherlands.

This article has been cited by other articles:

• Michallet, M., Ito, J. I. (2009). Approaches to the Management of Invasive Fungal Infections in Hematologic Malignancy and Hematopoietic Cell Transplantation. JCO 27: 3398-3409 [Abstract] [Full Text]  
• Maschmeyer, G. (2009). Prevention of mould infections. J Antimicrob Chemother 63: i27-i30 [Abstract] [Full Text]  
• Barnes, R A, White, P L, Bygrave, C, Evans, N, Healy, B, Kell, J (2009). Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. J. Clin. Pathol. 62: 64-69 [Abstract] [Full Text]  
• Collins, C. D., Ellis, J. J., Kaul, D. R. (2008). Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. Am J Health Syst Pharm 65: 2237-2243 [Abstract] [Full Text]  
• Pagano, L., Fianchi, L., Caira, M. (2008). Pulmonary aspergillosis in hematologic malignancies: lights and shadows. haematol 93: 1611-1616 [Full Text]  
• Rachwalski, E. J, Wieczorkiewicz, J. T, Scheetz, M. H (2008). Posaconazole: An Oral Triazole with an Extended Spectrum of Activity. The Annals of Pharmacotherapy 42: 1429-1438 [Abstract] [Full Text]  
• LONGWORTH, D. L. (2008). Update in infectious disease treatment. Cleveland Clinic Journal of Medicine 75: 584-590 [Abstract] [Full Text]  
• Bulpa, P., Dive, A., Sibille, Y. (2007). Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J 30: 782-800 [Abstract] [Full Text]  
• (2007). Posaconazole Superior to Fluconazole for Preventing Aspergillosis. JWatch Infect. Diseases 2007: 1-1 [Full Text]